Sera of 12 patients with quinine/quinidine-induced thrombocytopenia showed drug-dependent antibody binding t o glycoprotein (GP) Ib-IX complex. The reaction with GPlb-IX complex of 11 of these 12 sera was strongly inhibited by the complex-specific monoclonal antibodies (MoAbs) AK1 and SZ1. The exception was a quinine-induced serum designated BU. The reaction of the six quinidine-induced sera was also partially blocked by an anti-GPIX MoAb, FMC25. Only 3 of the 12 patient sera showed drug-dependent antibody binding t o GPllb/llla, which was strongly inhibited by the anti-GPllla MoAb 22C4, and the anti-GPllbu MoAb SZ22. With detergentsolubilized Serratia metalloprotease-treated platelets, quinine/quinidine-induced sera, except BU, immunoprecipitated a membrane-bound proteolytic fragment of GPlb-IX complex. In contrast, BU immunoprecipitated glycocalicin and a 40-Kd peptide tail fragment of GPlbu from the cell supernatant. Using purified GPIb-IX complex or its components as the target antigen, all the quinine-induced sera, except BU, HROMBOCYTOPENIA is a well-recognized compli-T cation in patients treated with quinine and quinidine.
T cation in patients treated with quinine and quinidine.
Patients with quininelquinidine-induced thrombocytopenia develop a drug-dependent antibody that binds to platelets in the presence of the drug causing platelet clearance. It has been previously proposed that the antibody binds the drug, resulting in an immune complex that is then adsorbed onto platelets.' Antigen-antibody complexes are usually adsorbed to cells by binding to cell membrane Fc receptors through the activated Fc domain of the antibody. However, there is now strong evidence that the binding of quinine1 quinidine-dependent antibodies to platelets is mediated by their Fab domain and is not Fc-de~endent. ' .~
The identity of the platelet membrane component involved in the binding of the quinineJquinidine-dependent antibody was not known until 1978 when Kunicki et a15 reported that the quinineJquinidine-dependent antibodies failed to react with Bernard-Soulier syndrome (BSS) platelets. This observation suggests that the binding domains of the drug-dependent antibodies reside on one or more of the absent membrane glycoproteins (GPs) in BSS platelets, immunoprecipitated GPlb-IX complex but failed t o immunoprecipitate GPlb, GPIX, or the complex reformed from GPlb and GPIX. The quinidine-induced sera strongly immunoprecipitated purified GPlb-IX complex, weakly immunoprecipitated purified GPIX and the recombined complex, but did not immunoprecipitate purified GPlb. The combined data suggest that one quinine-dependent antibody (BU) recognizes an epitope in the peptide tail region of GPIbu and the other five quinine-dependent antibodies react with a complexspecific epitope on the membrane-associated region of GPlb-IX complex, whereas each of the six quinidine-induced sera contain two drug-dependent antibodies, one reactive with the GPIb-IX complex-specific epitope and the other reactive with GPIX. The binding domainls) on GPllb/llla for the quinine/quinidine-dependent antibodies appear to be sterically close t o the epitopes for 22C4 and SZ22.
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namely GPIb, GPV, and GPIX. 6 We as well as others subsequently provided direct evidence that the quinine/ quinidine-dependent antibodies bind to the platelet membrane GPIb-IX ~omplex.~~'~* Recently, Christie et a19 found that the quininelquinidine-dependent antibodies may also bind to platelet GPIIbJIIIa complex. Therefore, there is now little doubt that the sera of patients with quinine1 quinidine-induced thrombocytopenia contain drug-dependent antibodies that react with GPIb-IX complex or GPIIbI IIIa complex or both. In those patient sera that react with both, two distinct antibodies, one specific for GPIb-IX complex and the other for GPIIbJIIIa complex, have been demonstrated.','' However, the relative frequencies and titers of the two drug antibodies in these patients are still uncertain. Moreover, the binding domains for these antibodies on the GPIb-IX and GPIIbIIIIa complexes have yet to be precisely defined.
In the present study, we investigate 12 patients with quininelquinidine-induced thrombocytopenia to address these questions, with an emphasis on mapping the binding domains on GPIb-IX for the drug-dependent antibodies using purified GPIb-IX complex and its components as well as monoclonal antibodies (MoAbs) directed against epitopes on various parts of the GP complex.
DRUG-INDUCED THROMBOCYTOPENIA
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from Pharmacia (Uppsala, Sweden). Serratia marcexens metalloprotease was the generous gift of Dr T. Kunicki (Milwaukee, WI). An anti-Pl*' antiplatelet antibody was obtained from a previously reported patient with posttransfusion purpura."
All MoAbs were of the IgG class and have been previously described. Several of the MoAbs were generous gifts: AP2 and AP3 from Dr T.J. Kunicki and Dr P.J. Newman, respectively (Milwaukee, WI), SZ1, SZ21, and SZ22 from Dr C. Ruan (Suzhou, China); FMC25 from Dr H. Zola (Adelaide, Australia), and PM1-1 and 22C4 from Dr E.F. Plow and Dr M.H. Ginsberg (La Jolla, CA). The remaining antibodies were raised and characterized in one of our laboratories in conjunction with A. Kabral (Westmead Hospital, Australia). AK1, AK2, AK3, SZ1, and FMC25 are all directed against epitopes on various parts of the human platelet GPIb-IX complex'*^" (see Fig 3) . AP2, AP3, SZ21, SZ22, PM1-1, and 22C4 are directed against epitopes on various parts of the human platelet GPIIbiIIIa complex.l*~'el'
Monoclonal IgG was purified from mouse ascites or cell culture supernatant by performing two 0% to 40% ammonium sulfate fractionations followed by protein A-Sepharose chromatography as previously described." The purified IgG was greater than 95% homogenous as assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Sera from six patients with quinineinduced thrombocytopenia (BU, CL, CO, GN, KE, and LO) and six patients with quinidine-induced thrombocytopenia (AN, DA, GA, WM, WI, and YO) were used in these studies. These patients developed thrombocytopenia when they were receiving quinine or quinidine and their thrombocytopenia resolved after cessation of the drug. Other causes of thrombocytopenia were clinically excluded. These sera were collected from the patients soon after withdrawal of the offending drug and were found by the indirect platelet immunofluorescence test to contain IgG quinineiquinidinedependent platelet antibodies.
Blood was collected from healthy volunteers into acid-citrate-dextrose (ACD) that contained 2.5% (wtivol) trisodium citrate, 2% (wtivol) D-glucose, and 1.5% (wthrol) citric acid (1 part ACD to 6 parts blood). Platelet-rich plasma (PRP) was prepared and the platelets were then washed as previously de~cribed.~ The washed platelets were suspended at 109/mL in EDTA-HEPES-saline (EHS) buffer that contained 0.01 mol/L HEPES, 0.15 m o m NaCI, and 0.001 moliL EDTA, pH 7.6. The platelet membrane GPs were labeled with sodium periodatei 'H-sodium borohydride as previously described.M In some experiments labeled platelets (109imL) were treated at 22°C for 1 hour with 10 pgimL or 100 pgimL of Serratia metalloprotease or saline (control). The reaction was terminated by adding 10 mmol/L EDTA. The platelets were then washed once and then lysed in the presence of leupeptin (200 pgimL) add phenylmethanesulfonyl flouride (0.2 mmoliL).
The MAIPA was performed as previously described with minor modifications." Blood was collected in EDTA (1 part 5% EDTA [wt/vol] to 9 parts blood). PRP was prepared, platelets isolated by centrifugation, and washed three times with PBS-EDTA buffer (Dulbec-CO'S phosphate-buffered saline containing 4 mmol EDTA and 0.01% sodium azide, pH 7.4). The platelets were stored at 4°C for 18 to 24 hours in this buffer. The platelet suspension was centrifuged at 2, OOOg for 5 minutes to give a total of 1 x 10' platelets. The platelets were resuspended in 50 pL PBS-EDTA buffer with 2% BSA and added to 75 pL of 1.5 mmol/L quinine/quinidine or saline, 200 pL of patient or control serum, 40 pL of MoAb (20 pg/mL, final concentration), and incubated at 37°C for 30 minutes. The platelets were pelleted and washed three times with PBS-EDTA buffer containing 0.3 mmol/L quinineiquinidine. The platelets were
MoAbs.
Drug-dependent antibodies.
Platelet preparation and labeling.
MoAb-spec@c immobilization of platelet antigens (MIPA).
lysed by resuspension in 0.01 m o m Tris-buffered saline (TBS) containing 0.5% Triton X-100, 0.05% Tween 20, and 0.3 mmol/L quinineiquinidine, pH 7.4. The platelet lysate was incubated for 30 minutes at 4°C and then centrifuged at 12,OOOg for 15 minutes at 4°C. The supernatant was diluted 1:5 with TBS buffer. The diluted supernatant (100 pL) was added to each well of a microtiter plate that had been coated with 100 pL of affinity purified sheep antimouse IgG (10 pg/mL in 0.05 moliL carbonate buffer) by overnight incubation at 4"C, washed, and blocked with 200 pL per well of TBS buffer for 30 minutes at 4°C. The microtiter plate was incubated for 90 minutes at 4°C and washed four times with TBS buffer. Antihuman IgG alkaline phosphatase conjugate (100 p L diluted 1:3,000 in TBS buffer) was added to each well and incubated for 120 minutes at 4°C. After six washes, 100 pL of substrate solution (p-nitrophenyl phosphate in diethanolamine buffer, pH 9.8) was added. The color reaction was stopped by addition of 3N NaOH after 40 minutes and read at 405 nm in a Titertek photometer (Labsystems, Finland). All tests were performed in triplicate. Results were expressed as the mean absorbance of the triplicate samples minus the mean absorbance of the blanks (wells without platelet lysate). A positive result is one in which the mean absorbance of the test sample is greater than the mean plus 3 SD of 30 normal sera.
Purification of t&ium-labeled GPIb-IX complq GPIb, and GPIX. Purification was performed as previously described.I2 Briefly, platelets from 10 U of less than 24-hour-old platelet concentrates were washed twice by centrifugation with citrate glucose saline, pH 7.0, and once with HEPES buffer, pH 7.4, containing 0.01 mol/L HEPES, 0.15 m o m NaC1, and 5 mmol/L EDTA. They were then suspended at 4 x lo9 platelets in 100 mL of HEPES buffer. The platelet suspension was made 1 mmol/L in sodium periodate, equilibrated for 10 minutes in the dark at OT, washed once by centrifugation, and resuspended to its original volume in the same buffer. The platelets were treated with 400 mCi of sodium 3H borohydride for 10 minutes*" and washed once by centrifugation. Platelet membrane extraction and purification of GPIb-IX complex on WM 23-Affigel 10 were performed as previously described.** Labeled GPIb was isolated from labeled GPIX by chromatography on FMC 25-AfligellO. To reconstitute the GPIb-IX complex, purified GPIb and GPIX were allowed to recombine by mixing together equivalent radioactive counts of each purified [3H]-labeled GP at 4°C for 12 hours."
Immunoprecipitation. Immunoprecipitation using four quinineinduced sera (sera of patients BU, CL, LO, and GN) and two quinidine-induced sera (sera of patients GA and WI) was performed as previously de~cribed.~ In the immunoprecipitation experiments the following samples were used: Triton X-100 lysates of tritium-labeled normal and Serratia metalloprotease-treated platelets, the supernatant from normal platelets and platelets treated with the protease (containing glycocalicin and its digestion products), radiolabeled GPIb-IX complex, GPIb, GPIX, and reconstituted GPIb-IX formed after labeled GPIb and labeled GPIX were allowed to recomplex.'* Patient serum (25 pL) and 25 pL of quinineiquinidine (0.3 mmol/L) were incubated with 200 pL of the appropriate sample at 4°C for 2 hours. Immunoprecipitation with fixed Staphylococcus aureus cells (Pansorbin) was then performed as previously de~cribed.~ Samples for SDS-PAGE were prepared by solubilization in 2% (wtivol) SDS in the absence (nonreduced) or presence (reduced) of 5% (volivol) P-mercaptoethanol. All samples were heated at 100°C for 5 minutes (nonreduced) or 10 minutes (reduced) to enhance solubilization of the sample. SDS-PAGE was performed according to the method of LaemmliZ3 using a 5% to 15% exponential gradient of acrylamide in the resolving gel and 3% acrylamide in the stacking gel. After completion of
SDS-PAGE.
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Reactions of the sera of patients with quinine/quinidineinduced thrombocytopenia with platelet GPlb-IX complex in the MAIPA assay using the MoAb AK2 in the presence or absence of the drug. Each point represents the reaction of one patient serum in the presence of the drug ( . ) or in the absence of the drug (A) and is the mean of triplicate readings. The mean reaction of 30 normal sera is 0.032 with SD = 0.032. A positive reaction is one in which the absorbance at 405 nm is greater than 0.128 (mean * 3 SD of 30 normal sera). A negative reaction is a reading below 0.128.
electrophoresis, the protein was stained with Coomassie brilliant blue and the tritium distribution in the dried gels was obtained by fluorography according to the method of Bonner and LaskeyF4
RESULTS
MAZPA studies. The sera of six patients who had quinineinduced thrombocytopenia and sera of six patients who had quinidine-induced thrombocytopenia were studied with the MAIPA technique initially using A K 2 (an MoAb that is directed against an epitope in the 40-Kd peptide tail region of the a-chain of GPIb, see Fig 3) . 13 The results are shown in Fig 1. All 12 patient sera showed positive but variable reactions with GPIb-IX complex in the presence of quinine/ quinidine. Only one patient serum (GN) gave a weakly positive reaction in the absence of the drug, but the reaction was enhanced in the presence of quinine. Normal sera plus quinineiquinidine always gave negative reactions. These findings indicate the presence of a quinineiquinidinedependent antibody that binds to GPIb-IX in each of the 12 patient sera and a drug-independent antibody in only one patient serum.
Further studies were performed to map the binding domains on the GPIb-IX complex for the 12 quinine/ quinidine-dependent antibodies using, in addition to AK2, four other MoAbs: AK3, which reacts with an epitope on the macroglycopeptide region of GPIbaI3; FMC25, which has specificity for GPIXI3; and AK1 and SZ1, which are directed against complex-specific epitopes on the GPIb-IX complex12 (see Fig 3) . The results of these studies are shown in Fig 2. On the basis of these results, the 12 sera could be divided into four groups. In group 1, five quinine-induced sera (CL, CO, GN, KE, and LO) were found to give For personal use only. on September 24, 2017. by guest www.bloodjournal.org From strongly positive reactions using AK2, AK3, or FMC25 in the MAIPA assays and negative results using the complexspecific MoAbs AK1 and SZ1 (Fig 2A) . These findings suggest that the quinine-dependent antibodies in these five sera attached to the GPIb-IX complex at a site remote from the epitopes of AK2, AK3, and FMC25. When platelets were incubated with patient serum plus drug and one of these MoAbs, a quadrimolecular complex consisting of the drug-dependent antibody, drug, GPIb-IX and the MoAb was formed; after platelet solubilization the quadrimolecular complex was transferred and successfully immobilized to the wells of the microtiter plates (Fig 3B[i] ). On the other hand, these quinine-dependent antibodies in the presence of the drug bound to the GPIb-IX complex at a site that either coincided with or was very close to the complexspecific epitope(s) of AKI and SKI so that the drugdependent antibody and AKI (SZI) cross-blocked the binding of each other to GPIb-IX, the quadrimolecular complex was not formed, and hence not immobilized to the microtiter plates ( Fig 3B[ii] ). The antibodies AKI and SZI were shown to be reactive with GPIb-IX under similar assay conditions using serum BU (Fig 2B) .
In group 2, one quinine-induced serum (BU) showed definitely positive although variable results with each of the five MoAbs, but the reaction was comparatively reduced with A K 2 (Fig 2B) . These findings suggest that the binding domain of the antibody, BU, may be situated relatively close to the epitope of AK2.
In group 3, five quinidine-induced sera (AN, DA, WI, WM, and YO), like the five quinine-induced sera, exhibited strong drug-dependent reactions with A K 2 and AK3 in the incubation mixture but negative results with AKI and SZI. However, they differed from the quinine-induced sera in that their reaction with the GPIb-IX complex was substantially reduced with the use of the anti-GPIX MoAb, FMC25, in the assay (Fig 2D) . In group 4, one quinidineinduced serum (GA) showed slightly different results from the other five quinidine-induced sera in that it exhibited positive although reduced reaction with the GPIb-IX complex when AK1 and SZ1 were used (Fig 2E) . One possible explanation for these findings is that group 3 and group 4 sera contained two drug-dependent antibodies, one reactive with a complex-specific epitope close to the binding site of AK1 and SZ1 and the other specific for GPIX.
To investigate further the binding domain of the unusual quinine-dependent antibody in the serum BU, MAIPA studies were performed with this serum and another quinine-induced serum CL (which was included for comparison) using platelets treated with Serratia metalloprotease (10 &mL) and untreated platelets (control). Treatment with a low concentration (10 pg/mL) of this protease cleaves off a major soluble portion of GPIba (glycocalicin) from GPIb (see Fig 3) . Using control platelets, both sera BU and CL showed unequivocal binding to the intact GPIb-IX complex immobilized by FMC25 (anti-GPIX) and AK3 (which binds to the macroglycopeptide region of glycocalicin). However, using proteasetreated platelets and FMC25 to bind the fragment of GPIb-IX that remained associated with the platelet membrane after proteolytic removal of glycocalicin ("membrane 
"), serum BU gave a negative result while serum CL still showed a positive reaction. These results suggest that the binding domain for antibody in serum BU is on the glycocalicin portion of GPIba and that for the antibody in serum CL it is on the membrane-associated region of the GPIb-IX complex. As expected, both antibodies BU and CL gave completely negative results with AK3 and protease-treated platelets that lack glycocalicin ( Table 1 ).
Antibodies that cross-reacted with the optical isomer of the "inducing"drug. Nine of the 12 patient sera were screened for cross-reaction with the optical isomer of the "inducing" drug using the MAIPA assay and initially using only AK2. There were insufficient sera from the other three patients for this experiment. Only one quinine-induced serum (BU) and one quinidine-induced serum (WI) showed crossreaction with the optical isomer of the drug that induced the immune response. The binding specificity of these two cross-reacting sera were then studied using the MAIPA assay with all five GPIb-IX-specific MoAbs (AK2, AK3, AKl, SZ1, and FMC25) and quininelquinidine. The results are shown in Fig 4. The antibody-binding specificity with each serum was the same with both quinine and quinidine, although in general the reactions were stronger with the "inducing" drug. The results were essentially unchanged from that of the earlier study on serum BU with quinine and serum WI with quinidine (Fig 2B and D) .
Immunoprecipitation. Immunoprecipitation studies were performed to further delineate the binding domains on GPIb-IX for the quininelquinidine-dependent antibodies using periodate-labeled platelets that had either been or not been (control) treated with Serratia metalloprotease (Fig 5 ) . Four quinine-induced sera (BU, CL, GN, and LO) and two quinidine-induced sera (WI and GA) were used in these studies with control platelets. All quinine/quinidineinduced sera immunoprecipitated the components of the GPIb-IX complex (GPIb, nonreduced molecular weight [mol wt] = 170 Kd and GPIX, nonreduced mol wt = 22 Kd) (Fig 5B) . With platelets that had been treated with Serratia metalloprotease (both at concentrations of 10 hg/L and 100 Fg/mL), the quininelquinidine-induced sera (CL, LO, GN, WI, and GA) immunoprecipitated a membraneassociated proteolytic fragment of GPIb-IX complex consisting of GPIX (mol wt = 22 Kd) and a remnant of GPIba that was disulfide-linked to GPIb, (mol wt = 55 Kd). No bands were observed with the supernatant of the metalloproteasetreated platelets, which contained glycocalicin and its digestive products. These findings were consistent with those of our previous s t u d i e~.~'~ However, the unusual quinine-induced serum, BU, yielded a band of mol wt = 140 Kd (glycocalicin) with the supernatant of the platelets treated with a low concentration of Serratia metalloprotease (IO & n L ) and two bands, an =14O-Kd band (glycocalicin) and a 40-Kd band, with the supernatant of platelets treated with a high concentration of Serratia metalloprotease (100 pg/mL). The 40-Kd band represents the proteolytic peptide tail fragment of the a-chain of GPIb. Apart from a faint contaminating 140-Kd band (glycocalicin), no other bands were seen with the lysate of platelets that had been treated with 10 Fg/mL of the metalloprotease. No bands were observed with the lysate of platelets that had been treated with 100 &mL of the metalloprotease. These data indicate that the binding domain of the quinine-dependent antibody in serum BU is on the 40-Kd peptide tail region of the a-subunit of GPIb. In contrast, the binding sites of the quininelquinidinedependent antibodies in other sera are on the membranebound proteolytic fragment of the GPIb-IX complex after glycocalicin has been cleaved off by the metalloprotease.
Additional immunoprecipitation studies were performed to define more precisely the binding domains on the GPIb-IX complex for the quinine/quinidine-dependent antibodies in these sera using tritium-labeled purified GPIb-IX complex, GPIb, GPIX, and reconstituted GPIb-IX complex (which was formed by allowing purified GPIb and GPIX to recomplex). With labeled, purified GPIb-IX complex as the target antigen, the quininelquinidine-induced sera (LO, GN, CL, WI, and GA) immunoprecipitated the compo- nents of the GPIb-IX complex (GPIb and its degradation product and GPIX) (Fig 6, C and D, lane 1) . No bands were observed with quinine-induced sera (LO, GN, and CL) when labeled purified GPIb, GPIX, or the reconstituted GPIb-IX complex was used as the target antigen. However, the quinidine-induced sera (WI and GA) gave a faint 22-Kd band (GPIX) with purified GPIX and two faint bands, 170 Kd (GPIb) and 22 Kd (GPIX), with reconstituted GPIb-IX complex but no band with purified GPIb.
The binding domains on GPIIblIIIa for the quinine/ quinidine-dependent antibodies. The results of MAIPA studies with the 12 patient sera using a battery of six MoAbs (which are directed against epitopes on various parts of the GPIIb/IIIa complex) are shown in Fig 7. AP2 recognizes a complex-specific epitope," AP3, and SZ21 and 22C4 are directed against epitopes on GPIIIa.14.15s1X SZ22 has specificity for GPIIba." PMI-I recognizes an epitope on the carboxyl terminus of GPIIba. 16 Only the sera of three patients contained drug-dependent antibodies that recognized the GPIIbIIIIa complex:
two patients with quinidine-induced thrombocytopenia (WM and GA) and one patient with quinine-induced thrombocytopenia (LO). In the presence of the drug, these three patient sera showed strongly positive reactions with the use of MoAbs SZ21, AP2, AP3 and PMI-1, but reduced or negative results with the use of MoAbs 22C4 and SZ22 in the MAIPA assays (Fig 7) .
With the other nine patient sera, completely negative results were obtained with each of the six GPIIbIIIIaspecific MoAbs. For comparison, the serum from a patient with posttransfusion purpura (containing anti-PIA1 antibody)" gave strongly positive reactions with each of the six MoAbs except SZ21. These findings suggest that the binding domains on the GPIIbIIIIa complex for the antibodies in these three quininelquinidine-induced sera are sterically close to the epitopes of 22C4 and SZ22.
C o m p a~o n of dmg-dependent anti-GPIb-IX antibodies and anti-GPIIblIZZa antibodies in sera ofpatients with quinine1 quinidine-induced thrombocytopenia. Drug-dependent antibodies that reacted with the GPIb-IX complex were found in all 12 patient sera, but drug-dependent antibodies that reacted with GPIIbDIIa were found in only three patient sera according to the results of the MAIPA studies. In the three patient sera (GA, WM, and LO) that contained both antibodies, the antibodies which reacted with the GPIb-IX complex consistently gave stronger reactions than the antibodies which reacted with the GPIIbIIIIa complex. In addition, the titer of the antibody that reacted with the GPIb-IX complex in each patient serum was 8- higher than that which rccognizcd GPIIb/lIla (data not shown).
tion of the mcmbranc-associated protcolytic fragmcnt of thc GPIb-IX complex (Fig 5) , comprising GPlX (mol wt = 22 Kd) and a remnant of the a-subunit of GPIb DISCUSSION disulfidc linked to thc pthain of GPIb (mol wt = 55 Kd). It is now clear that the sera of patients with quinine/ Thcsc data wcrc consistent with our previous report, which quinidinc-induced thrombocytopcnia may contain druguscd a drug-dependcnt antibody from a different patient.' dcpcndcnt antibodics that rcact with platclct GPIb-IX Although immunoprccipitation analysis was not performed complcx and thc GPIlb/llla complcx.'.'~'" Our data suggest on thc othcr six patient scra, MAIPA studies of these that the drug-dcpcndcnt antibodics that rcact with the patient scra gavc similar results to thc previously dcscribcd GPlb-IX complcx arc the prcdominant antibodies. Thcy fivc-patient scra. suggesting that thc binding domains of thc arc found in thc scra of all of our 12 paticnts with quininc/quinidinc-dcpcndcnt antibodies in thcsc six scra quininc/quinidinc-induccd thrombocytopenia. In contrast, wcrc also likely to be in the membrane-associated region of thc drug-dcpcndcnt antibodies with spccificity for GPIIW the GPlb-IX complcx. llla wcrc dctcctcd only in thrcc of our patients. In addition, Thc binding site of one quininc-dcpendent antibody the drug-dcpcndcnt antibodies with spccificity for thc (BU) was clcarly diffcrent from thosc of the drugGPlb-IX complcx wcrc morc strongly positive in the dcpcndent antibodies. Three lincs of evidence suggest that MAIPA assays and wcrc prcscnt in titers 8-to 32-fold this antibody (BU) reactcd in the prescncc of quinine with higher than the corresponding antibodies with specificity an cpitopc on thc glycocalicin region of the GPlb. Firstly, for GPllb/Illa in the samc patient scrum. However, thrcc the drug-dependent reaction of the patient scrum (BU) previous studies'.'".'' did not find such a marked diffcrcncc with GPlb-IX complex was partially inhibitcd by thc MoAb in frcqucncy bctween the two antibodies.
AK2 (which is dirccted against an cpitopc on thc peptide In the prcscnt study, the majority of the drug-dcpcndcnt tail of GPlba). Sccondly, this quinine-dcpcndcnt antibody antibodies that reactcd with GPlb-IX were found to bind to was found to bind to intact GPIb-IX complex but failcd to thc membrane-associated region of the GPlb-IX complex.
bind in thc prescncc of thc drug to the protcolytic fragmcnt With Serratia metalloproteasc-treated platclcts, five patient of thc GPIb-IX complex after removal of glycocalicin by scra gavc quinindquinidine-dependent immunoprccipitaSerruria mctalloprotcasc (Table 1) . Thirdly, this patient serum gave quinine-dependent immunoprecipitation of glycocalicin (140-Kd band) with the supernatant of platelets treated with a low concentration of Serratia metalloprotease (10 yg/mL) and drug-dependent immunoprecipitation of glycocalicin, and a 40-Kd mol wt peptide tail remnant of GPIba with the supernatant of platelets treated with a high concentration of the protease (100 yg/mL). The results of the immunoprecipitation studies indicate that the binding domain of this quinine-dependent antibody is located on the peptide tail region of the a-chain of GPIb (see Fig 3) . A drug-dependent antibody with such an unusual specificity has not been previously reported.
The results of the MAIPA studies (Fig 2) clearly indicate that the binding domains of all the quinine-dependent antibodies, except the antibody BU, either coincided with or were located very close to the complex-specific epitope(s) 
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Patient serum, quinine, and MoAb AK3 or FMC25 were incubated with control and Serratia metalloprotease-treated platelets, and MAIPA assays were then performed as described in Materials and Methods.
of MoAbs AK1 and SZ1," as these two MoAbs strongly inhibited the binding of the quinine-dependent antibodies to the GPIb-IX complex. In support of this, the quininedependent antibodies in the presence of quinine immunoprecipitated purified GPIb-IX complex but did not immunoprecipitate the individual purified components of this complex, GPIb or GPIX, nor did they immunoprecipitate the reformed complex when isolated GPIb and GPIX were allowed to recombine. These immunoprecipitation data are consistent with our previous finding4 that purified GPIb-IX complex inhibited binding of the drug-dependent antibody to platelets, but both isolated GPIb and GPIX individually were ineffective. The combined data suggest the binding domains of the quinine-dependent antibodies were ex-'tremely sensitive to dissociation of the complex and were irreversibly disrupted when GPIb was separated from GPIX. Although the tertiary structure of the binding domains for quinine-dependent antibodies appears to be dependent on the normal interaction of GPIb and GPIX, it is still uncertain if the actual binding site is either on one or both of the components of the GPIb-IX complex.
The MAIPA studies with the quinidine-dependent antibodies showed that the complex-specific MoAbs AK1 and SZ1 strongly inhibited the reaction of five quinidineinduced sera with GPIb-IX complex (group 3) and partially blocked the reaction of one quinidine-induced serum, GA (group 4). The anti-GPIX MoAb FMC25 also partially For personal use only. on September 24, 2017. by guest www.bloodjournal.org From blocked the reaction of all six quinidine-induced sera with the GP complex. The most likely explanation of these results is that each of these six sera contained two different quinidine-dependent antibodies, one specific for GPIX and the other reactive with a GPIb-IX complex-specific epitope close to the binding site(s) of AKl and SZ1. An alternative interpretation of these results is that there was only one quinidine-dependent antibody in each patient serum. The binding site of this antibody was different from that of the five quinine-dependent antibodies and was located close to the epitopes of FMC25, AK1, and SZ1. In the light of the data on the binding specificities of the cross-reacting sera (BU and WI), this interpretation seems less likely as the cross-reacting drug-dependent antibodies showed no difference in their binding specificities between quinine and quinidine (Fig 4) .
Cross-blocking studies reported previously showed that AK1 and SZ1 completely blocked the binding of each other to GPIb-IX and inhibited the binding of FMC25 by = 50% and 80%, respectively." Conversely, FMC25 blocked the binding of AK1 and SZ1 by only ~2 5 % and 30%, respectively. The complex-specific MoAbs AK1 and SZ1 appeared to be more effective in blocking the binding of the GPIX-specific MoAb FMC25, but not vice versa. It is not surprising that AK1 and SZ1 caused more pronounced inhibition on drug-dependent antibody binding than FMC25 with the five "group 3" quinidine-induced sera. The reason for the partial inhibition by AKI and SZI of the reaction of the quinidine-induced serum (GA) with GPIb-IX complex is unclear and could possibly be attributed to a difference in the relative titer and/or avidity of the GPIX-specific and the complex-specific drug-dependent antibodies in the serum.
The results of the immunoprecipitation study confirmed the findings of the MAIPA study. It showed strong reaction of the quinidine-induced sera with purified GPIb-IX complex, weak reaction with purified GPIX and the reconstituted complex, but no reaction with purified GPIb (both WI and GA gave the same results). These findings again suggest the presence of two antibodies in the quinidineinduced sera. Both the GPIX-specific and the GPIb-IX complex-specific quinidine-dependent antibodies were responsible for the strong reaction with the intact complex, but the GPIX-specific antibody alone was responsible for the reaction with GPIX and the reconstituted complex. Partial irreversible disruption of the epitope of the GPIXspecific antibody might have occurred when GPIX was dissociated from GPIb during the purification process, and this could account for the weak reaction of this antibody with purified GPIX and the reconstituted complex.
The binding domains on the GPIIb/IIIa complex for the quininelquinidine-dependent antibodies were less extensively studied. The quinineiquinidine-dependent antibodies bound to GPIIbiIIIa at a site sterically very close to the epitope of 22C4, as this anti-GPIIIa MoAb completely inhibited the reaction of the drug-dependent antibodies with the GP complex. The binding domains of the drugdependent antibodies were also sterically related to the epitope of the MoAb SZ22, which is directed against the a-chain of GPIIb.''
The combined evidence suggests that the majority of quinineiquinidine-dependent antibodies bind to GPIb-IX and GPIIbiIIIa complexes at specific sites on the two GP complexes. Because the protein structures and amino acid sequences of the are now known, it may be possible with further studies to determine what common features on the GPIb-IX and GPIIbiIIIa complexes predispose them as target antigens for drug-dependent autoantibodies.
